Position in GILD
as of Jun 30, 2026
· filed Aug 3, 2026
Position Value
$551,853
-$73,360 QoQ
Shares Held
4,368
-2.6% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#1,332
of 2,266 holders
Holding Since
Dec 2023
10 quarters on record
Voting authority
Sole 5%
Shared 0%
None 95%
Common Shares in GILD Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Bryn Mawr Trust Advisors, LLC holds $73,679,493 across 10 Drug Manufacturers - General names. GILD ranks #9 (0.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MRK |
Merck & Co., Inc.
|
220,148 | $28,289,018 | |
| 2 | JNJ |
Johnson & Johnson
|
107,673 | $27,345,711 | |
| 3 | AZN |
Astrazeneca PLC
|
27,799 | $5,271,246 | |
| 4 | LLY |
ELI LILLY & Co
|
3,407 | $4,086,458 | |
| 5 | AMGN |
Amgen Inc
|
9,560 | $3,461,867 | |
| 6 | ABBV |
AbbVie Inc.
|
8,879 | $2,234,311 | |
| 7 | PFE |
Pfizer Inc
|
49,991 | $1,203,783 | |
| 8 | NVS |
Novartis AG
|
5,909 | $926,058 |
All Filings in GILD
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $551,853 | 4,368 | Shares | Sole | 2026-08-03 | |
| 2026-03-31 | $625,213 | 4,486 | Shares | Sole | 2026-05-04 | |
| 2025-12-31 | $406,883 | 3,315 | Shares | Sole | 2026-02-04 | |
| 2025-09-30 | $384,171 | 3,461 | Shares | Sole | 2025-11-04 | |
| 2025-06-30 | $319,305 | 2,880 | Shares | Sole | 2025-08-06 | |
| 2025-03-31 | $302,759 | 2,702 | Shares | Sole | 2025-05-02 | |
| 2024-12-31 | $246,997 | 2,674 | Shares | Sole | 2025-02-05 | |
| 2024-09-30 | $226,368 | 2,700 | Shares | Sole | 2024-10-25 | |
| 2024-03-31 | $205,100 | 2,800 | Shares | Sole | 2024-05-02 | |
| 2023-12-31 | $230,878 | 2,850 | Shares | Sole | 2024-02-02 | |
| No filing history on record for this holder in this stock. | ||||||